IONIS ENAC 2.5Rx

Drug Profile

IONIS ENAC 2.5Rx

Alternative Names: ENaC ASO - Ionis Pharmaceuticals; Generation 2.5 ENaC antisense oligonucleotide - Ionis Pharmaceuticals; Generation 2.5 ENaC ASOs - Ionis Pharmaceuticals; ION-827359; IONIS-ENAC-2.5Rx; IONIS-ENaCRx

Latest Information Update: 16 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ionis Pharmaceuticals
  • Developer Cystic Fibrosis Foundation; Ionis Pharmaceuticals
  • Class Antifibrotics; Antisense oligonucleotides
  • Mechanism of Action Epithelial sodium channel-antagonists; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cystic fibrosis

Most Recent Events

  • 29 Aug 2018 Ionis Pharmaceuticals plans a phase I trial for Cystic fibrosis (In volunteers) (Inhalation) in November 2018 (EudraCT2018-002621-27) (NCT03647228)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top